Randomized Study Of Dacarbazine Versus Dacarbazine Plus G3139 (Bcl-2 Antisense Oligonucleotide) In Patients With Advanced Malignant Melanoma

Trial Profile

Randomized Study Of Dacarbazine Versus Dacarbazine Plus G3139 (Bcl-2 Antisense Oligonucleotide) In Patients With Advanced Malignant Melanoma

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jun 2011

At a glance

  • Drugs Dacarbazine; Oblimersen
  • Indications Malignant melanoma
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2011 Results of an pooled exploratory analysis for PFS of this study and the AGENDA study presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
    • 12 Jan 2011 Assessment of the late endpoints of durable response and overall survival will conclude at the end of quarter 1, 2011, with release of these data expected early Q2 2011, according to a Genta media release.
    • 07 Jun 2010 Pooled overall response and progression-free survival results of the AGENDA (700022707) and GM301 trials presented at ASCO, according to a Genta media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top